BACKGROUND AND PURPOSE: Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients. METHODS: Nine patients with Friedreich ataxia underwent Diffusion Tensor Imaging (DTI) before and after EPO treatment. Tract-based spatial statistics was used for longitudinal comparison. RESULTS: We detected widespread longitudinal increase in fractional anisotropy and axial diffusivity (D||) in cerebral hemispheres bilaterally (P < .05, corrected), while no changes were observed within the cerebellum, medulla oblongata, and pons. CONCLUSIONS: To the best of our knowledge, this is the first DTI study to investigate the effects of EPO in a neurodegenerative disease. Anatomically, the diffusivity changes appear disease unspecific, and their biological underpinnings deserve further study.
BACKGROUND AND PURPOSE:Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients. METHODS: Nine patients with Friedreich ataxia underwent Diffusion Tensor Imaging (DTI) before and after EPO treatment. Tract-based spatial statistics was used for longitudinal comparison. RESULTS: We detected widespread longitudinal increase in fractional anisotropy and axial diffusivity (D||) in cerebral hemispheres bilaterally (P < .05, corrected), while no changes were observed within the cerebellum, medulla oblongata, and pons. CONCLUSIONS: To the best of our knowledge, this is the first DTI study to investigate the effects of EPO in a neurodegenerative disease. Anatomically, the diffusivity changes appear disease unspecific, and their biological underpinnings deserve further study.
Authors: Laura A Harsan; Patrick Poulet; Blandine Guignard; Jérôme Steibel; Nathalie Parizel; Paulo Loureiro de Sousa; Nelly Boehm; Daniel Grucker; M Said Ghandour Journal: J Neurosci Res Date: 2006-02-15 Impact factor: 4.164
Authors: D R Lynch; J M Farmer; A Y Tsou; S Perlman; S H Subramony; C M Gomez; T Ashizawa; G R Wilmot; R B Wilson; L J Balcer Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: B Sturm; D Stupphann; C Kaun; S Boesch; M Schranzhofer; J Wojta; H Goldenberg; B Scheiber-Mojdehkar Journal: Eur J Clin Invest Date: 2005-11 Impact factor: 4.686
Authors: Stephen M Smith; Mark Jenkinson; Heidi Johansen-Berg; Daniel Rueckert; Thomas E Nichols; Clare E Mackay; Kate E Watkins; Olga Ciccarelli; M Zaheer Cader; Paul M Matthews; Timothy E J Behrens Journal: Neuroimage Date: 2006-04-19 Impact factor: 6.556
Authors: Louise A Corben; Felicity Klopper; Monique Stagnitti; Nellie Georgiou-Karistianis; John L Bradshaw; Gary Rance; Martin B Delatycki Journal: Cerebellum Date: 2017-08 Impact factor: 3.847
Authors: Pedro A Luque Laguna; Anna J E Combes; Johannes Streffer; Steven Einstein; Maarten Timmers; Steve C R Williams; Flavio Dell'Acqua Journal: Neuroimage Clin Date: 2020-01-25 Impact factor: 4.881